奥翔药业
(603229)
| 流通市值：68.58亿 | | | 总市值：68.58亿 |
| 流通股本：8.30亿 | | | 总股本：8.30亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 467,614,591.81 | 308,673,252.77 | 792,759,011.85 | 645,961,585.61 |
| 营业总成本 | 361,464,471.53 | 193,930,900.75 | 670,523,160.48 | 436,884,971.86 |
| 其他经营收益 | | | | |
| 营业利润 | 130,363,944.28 | 107,365,877.18 | 140,045,154.4 | 234,233,339.74 |
| 利润总额 | 130,294,602.53 | 107,330,659.49 | 137,903,857.48 | 233,345,728.07 |
| 净利润 | 119,840,785.42 | 96,662,497.25 | 130,570,123.6 | 207,031,905.94 |
| 每股收益 | | | | |
| 其他综合收益 | -263,400.55 | 199,836.82 | -262,560.71 | 19,962.48 |
| 综合收益总额 | 119,577,384.87 | 96,862,334.07 | 130,307,562.89 | 207,051,868.42 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,780,599,715.8 | 1,878,870,467.46 | 1,815,331,179.77 | 1,793,706,183.58 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,296,804,735.93 | 1,277,968,052.6 | 1,269,919,485.68 | 1,266,647,706.63 |
| 资产总计 | 3,077,404,451.73 | 3,156,838,520.06 | 3,085,250,665.45 | 3,060,353,890.21 |
| 流动负债: | | | | |
| 流动负债合计 | 602,037,780.71 | 711,085,662.81 | 736,019,871.51 | 631,624,715.86 |
| 非流动负债: | | | | |
| 非流动负债合计 | 86,431,072.52 | 78,566,579.27 | 79,872,580.31 | 81,428,542.32 |
| 负债合计 | 688,468,853.23 | 789,652,242.08 | 815,892,451.82 | 713,053,258.18 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,388,935,598.5 | 2,367,186,277.98 | 2,269,358,213.63 | 2,347,300,632.03 |
| 股东权益合计 | 2,388,935,598.5 | 2,367,186,277.98 | 2,269,358,213.63 | 2,347,300,632.03 |
| 负债和股东权益合计 | 3,077,404,451.73 | 3,156,838,520.06 | 3,085,250,665.45 | 3,060,353,890.21 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 349,505,476.86 | 188,380,264.34 | 984,246,886.73 | 720,011,893.88 |
| 经营活动现金流出小计 | 391,868,729.45 | 222,415,242.33 | 827,737,972.48 | 572,366,281.51 |
| 经营活动产生的现金流量净额 | -42,363,252.59 | -34,034,977.99 | 156,508,914.25 | 147,645,612.37 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 29,446,426.64 | 8,887,293.08 | 67,034,020.97 | 48,088,170.77 |
| 投资活动现金流出小计 | 54,423,232.7 | 30,180,011.68 | 125,457,198.33 | 95,925,955.17 |
| 投资活动产生的现金流量净额 | -24,976,806.06 | -21,292,718.6 | -58,423,177.36 | -47,837,784.4 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 216,375,895.24 | 101,602,116.48 | 524,517,726.44 | 307,896,522.55 |
| 筹资活动现金流出小计 | 331,314,383.58 | 93,972,034.93 | 474,066,371.82 | 373,013,518.93 |
| 筹资活动产生的现金流量净额 | -114,938,488.34 | 7,630,081.55 | 50,451,354.62 | -65,116,996.38 |
| 汇率变动对现金及现金等价物的影响 | -33,254,046.82 | -22,048,408.04 | -17,457,141.89 | -2,547,447.62 |
| 现金及现金等价物净增加额 | -215,532,593.81 | -69,746,023.08 | 131,079,949.62 | 32,143,383.97 |
| 期末现金及现金等价物余额 | 964,128,574.96 | 1,109,915,145.69 | 1,179,661,168.77 | 1,080,724,603.12 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -215,532,593.81 | - | 131,079,949.62 | - |